Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel; Gemcitabine; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 27 Mar 2018 Planned number of patients changed from 58 to 62.
- 07 Feb 2017 New trial record
- 02 Feb 2017 Status changed from not yet recruiting to recruiting.